![Mitsuo Fujinami](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Mitsuo Fujinami
Private Equity Investor chez BioFrontier Partners, Inc.
Provenance du réseau au premier degré de Mitsuo Fujinami
Entité | Type d'entité | Industrie | |
---|---|---|---|
BioFrontier Partners, Inc.
![]() BioFrontier Partners, Inc. Investment ManagersFinance BioFrontier Partners Inc (BioFrontier Partners) is a venture capital firm founded in 2000. The firm is headquartered in Tokyo, Japan.
2
| Private Company | Investment Managers | 2 |
Graphique Sociétés connectées au second degré
Relation dans plusieurs entreprises
Sociétés connectées à Mitsuo Fujinami via son réseau personnel
Société | Secteur | Personnes liées | Poste principal |
---|---|---|---|
HUMAN METABOLOME TECHNOLOGIES, INC. | Biotechnology | Founder | |
Tohoku University | College/University | Doctorate Degree | |
GeneCare Research Institute Co., Ltd.
![]() GeneCare Research Institute Co., Ltd. Medical/Nursing ServicesHealth Services GeneCare Research Institute Co., Ltd. engages in the research, development, and drug discovery of treatments in the field of cancer, inflammation, hepatic carcinoma and rheumatism. It provides the distribution services for its products through their direct customers, which includes pharmaceutical companies and clinical-related companies. The company was founded by Yasuhiro Furuichi on December 20, 2000 and is headquartered in Kamakura, Japan. | Medical/Nursing Services | Director/Board Member | |
Healthcare Innovation Co. Ltd.
![]() Healthcare Innovation Co. Ltd. Investment ManagersFinance Healthcare Innovation Co. Ltd. (Healthcare Innovation) is a Venture Capital firm founded in 2017. The firm is headquartered in Tokyo, Japan. | Investment Managers | Chairman | |
Cell-Medicine, Inc.
![]() Cell-Medicine, Inc. Pharmaceuticals: MajorHealth Technology Cell-Medicine, Inc. is a Japanese company that specializes in cancer immunotherapy based on scientific evidence. The private company is based in Tsukuba, Japan. The company aims to prevent the recurrence of cancer after surgery, prevent metastasis, and treat remaining cancer. The company's self-cancer vaccine therapy is based on scientific evidence and is designed to target recurring and metastasizing cancer after surgery, as well as treat remaining cancer. The company was founded in 2001 by Tadao Ono. | Pharmaceuticals: Major | Director/Board Member | |
Texas A&M University | College/University | Graduate Degree |
Statistiques
Internationale
Japon | 6 |
Etats-Unis | 2 |
Sectorielle
Health Technology | 3 |
Consumer Services | 3 |
Health Services | 2 |
Finance | 2 |
Opérationnelle
Chairman | 2 |
Director/Board Member | 2 |
President | 1 |
Founder | 1 |
Doctorate Degree | 1 |
Relations les plus connectées
Insiders | |
---|---|
Yoshihiro Otaki | 6 |
Hinako Schroeter | 2 |
- Bourse
- Insiders
- Mitsuo Fujinami
- Connexions Sociétés